TWI803511B - 嗎啉基吡啶酮化合物 - Google Patents

嗎啉基吡啶酮化合物 Download PDF

Info

Publication number
TWI803511B
TWI803511B TW107129499A TW107129499A TWI803511B TW I803511 B TWI803511 B TW I803511B TW 107129499 A TW107129499 A TW 107129499A TW 107129499 A TW107129499 A TW 107129499A TW I803511 B TWI803511 B TW I803511B
Authority
TW
Taiwan
Prior art keywords
trifluoromethyl
compound
cancer
pharmaceutically acceptable
pyridin
Prior art date
Application number
TW107129499A
Other languages
English (en)
Chinese (zh)
Other versions
TW201912161A (zh
Inventor
銪寒 藺斯德勒姆
利卡德 弗斯布隆姆
燕妮 維克隆德
Original Assignee
瑞典商斯普林特生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商斯普林特生物科技公司 filed Critical 瑞典商斯普林特生物科技公司
Publication of TW201912161A publication Critical patent/TW201912161A/zh
Application granted granted Critical
Publication of TWI803511B publication Critical patent/TWI803511B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107129499A 2017-08-23 2018-08-23 嗎啉基吡啶酮化合物 TWI803511B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567.7 2017-08-23
EP17187567 2017-08-23
??17187567.7 2017-08-23

Publications (2)

Publication Number Publication Date
TW201912161A TW201912161A (zh) 2019-04-01
TWI803511B true TWI803511B (zh) 2023-06-01

Family

ID=59686888

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112116474A TW202348601A (zh) 2017-08-23 2018-08-23 嗎啉基吡啶酮化合物
TW107129499A TWI803511B (zh) 2017-08-23 2018-08-23 嗎啉基吡啶酮化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW112116474A TW202348601A (zh) 2017-08-23 2018-08-23 嗎啉基吡啶酮化合物

Country Status (20)

Country Link
US (2) US11560374B2 (OSRAM)
EP (2) EP4056569A1 (OSRAM)
JP (2) JP7199736B2 (OSRAM)
KR (1) KR102732013B1 (OSRAM)
CN (3) CN111108102B (OSRAM)
AU (2) AU2018320419B2 (OSRAM)
CY (1) CY1125117T1 (OSRAM)
DK (1) DK3672962T3 (OSRAM)
ES (1) ES2910157T3 (OSRAM)
HR (1) HRP20220497T1 (OSRAM)
HU (1) HUE058661T2 (OSRAM)
IL (3) IL302077A (OSRAM)
LT (1) LT3672962T (OSRAM)
PL (1) PL3672962T3 (OSRAM)
PT (1) PT3672962T (OSRAM)
RS (1) RS63109B1 (OSRAM)
SI (1) SI3672962T1 (OSRAM)
SM (1) SMT202200169T1 (OSRAM)
TW (2) TW202348601A (OSRAM)
WO (1) WO2019038390A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550641A (ja) * 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ,エルエルシー ウイルス感染症の治療に使用するためのvsp34阻害剤としてのモルホリノ誘導体
CN117241800A (zh) * 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
WO2022115562A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
TW201402577A (zh) * 2012-06-22 2014-01-16 Sanofi Sa 包含經取代嗎福啉之新穎2,3-二氫-1H-咪唑并{1,2-a}嘧啶-5-酮及1,2,3,4-四氫嘧啶并{1,2-a}嘧啶-6-酮衍生物,其製備及其醫療用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622486B2 (en) * 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
MX2013007336A (es) 2010-12-21 2013-08-01 Novartis Ag Compuestos de bi-heteroarilo como inhibidores de vps34.
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
CN105916503B (zh) 2014-01-14 2020-04-14 米伦纽姆医药公司 杂芳基化合物和其用途
JP2017502092A (ja) 2014-01-14 2017-01-19 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリール及びその使用
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN108884067B (zh) * 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
PT3416945T (pt) * 2016-02-19 2020-09-11 Sprint Bioscience Ab Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
TW201402577A (zh) * 2012-06-22 2014-01-16 Sanofi Sa 包含經取代嗎福啉之新穎2,3-二氫-1H-咪唑并{1,2-a}嘧啶-5-酮及1,2,3,4-四氫嘧啶并{1,2-a}嘧啶-6-酮衍生物,其製備及其醫療用途

Also Published As

Publication number Publication date
EP3672962A1 (en) 2020-07-01
ES2910157T3 (es) 2022-05-11
LT3672962T (lt) 2022-05-10
HRP20220497T1 (hr) 2022-05-27
AU2018320419A1 (en) 2020-04-09
US20200361922A1 (en) 2020-11-19
CA3073142A1 (en) 2019-02-28
IL272815B (en) 2022-06-01
DK3672962T3 (da) 2022-05-02
WO2019038390A1 (en) 2019-02-28
KR102732013B1 (ko) 2024-11-18
CY1125117T1 (el) 2024-12-13
EP4056569A1 (en) 2022-09-14
IL302077A (en) 2023-06-01
SI3672962T1 (sl) 2022-06-30
CN111108102B (zh) 2023-04-28
IL272815A (en) 2020-04-30
US20230234949A1 (en) 2023-07-27
HUE058661T2 (hu) 2022-09-28
EP3672962B1 (en) 2022-01-26
JP2020531485A (ja) 2020-11-05
CN116462674A (zh) 2023-07-21
JP7199736B2 (ja) 2023-01-06
IL292489B2 (en) 2023-09-01
RS63109B1 (sr) 2022-04-29
AU2018320419B2 (en) 2023-09-28
AU2023285995A1 (en) 2024-01-25
IL292489B1 (en) 2023-05-01
JP2023021268A (ja) 2023-02-10
CN111108102A (zh) 2020-05-05
TW201912161A (zh) 2019-04-01
PT3672962T (pt) 2022-04-12
US11560374B2 (en) 2023-01-24
RU2020110506A (ru) 2021-09-23
IL292489A (en) 2022-06-01
KR20200044025A (ko) 2020-04-28
RU2020110506A3 (OSRAM) 2022-02-22
PL3672962T3 (pl) 2022-05-02
CN116444510A (zh) 2023-07-18
SMT202200169T1 (it) 2022-05-12
TW202348601A (zh) 2023-12-16

Similar Documents

Publication Publication Date Title
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
CN108884067A (zh) 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
JP2023021268A (ja) モルホリニルピリドン化合物
TW202308996A (zh) 吡啶基吡啶酮化合物
TWI785101B (zh) 氮雜吲哚基吡啶酮及二氮雜吲哚基吡啶酮化合物
RU2803158C2 (ru) Морфолинилпиридоны
CA3073142C (en) Morpholinylpyridone compounds
HK40079060A (en) Morpholinylpyridone compounds
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees